Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 9/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23159584 | 0.83 | TSHR (0.33) | TSHRHTR1AHTR2CTP53SMN1; SMN2 | |
| SCHEMBL21307302 | 0.78 | NOTUM (0.42) | TSHRCNR2HTR1AHTR2CTP53 | |
| SCHEMBL21295037 | 0.72 | TSHR (0.33) | TSHRCNR2HTR1AHTR2CTP53 | |
| SCHEMBL21295057 | 0.71 | TSHR (0.33) | TSHRCNR2HTR1AHTR2CTP53 | |
| SCHEMBL21295072 | 0.68 | TSHR (0.48) | TSHRTP53SMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL21295048 | 0.68 | FEN1 (0.36) | TSHRL3MBTL1LMNA | |
| SCHEMBL21295089 | 0.68 | FEN1 (0.36) | TSHRCNR2TP53L3MBTL1LMNA | |
| SCHEMBL22855746 | 0.64 | TSHR (0.36) | TSHRCNR2L3MBTL1LMNA | |
| SCHEMBL21295047 | 0.64 | TSHR (0.49) | TSHRTP53SMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL19610383 | 0.61 | KDM1A (0.40) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021057910-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2021-04-01 | — | — | WO | disclosed |